Header Logo

Connection

Christopher Goetz to Movement Disorders

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Movement Disorders.
Christopher Goetz
Connection Strength
9.081
Movement Disorders
  1. Reply to: "The Framework for Diagnostic Criteria in Movement Disorders: The Value of Methodological Tools and Combined Criteria". Mov Disord. 2023 09; 38(9):1763-1764.
    View in: PubMed
    Score: 0.836
  2. Implementation and Outcomes of a Movement Disorder Society-Sponsored Peer Reviewing Education and Mentoring Program. Mov Disord. 2022 05; 37(5):1093-1097.
    View in: PubMed
    Score: 0.755
  3. Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice? Mov Disord. 2021 07; 36(7):1481-1482.
    View in: PubMed
    Score: 0.721
  4. Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era. Mov Disord. 2020 06; 35(6):911.
    View in: PubMed
    Score: 0.665
  5. Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2018 07; 33(7):1189-1190.
    View in: PubMed
    Score: 0.585
  6. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.480
  7. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.388
  8. Dopamine dysregulation syndrome item from the MDS-UPDRS. Mov Disord. 2012 Jan; 27(1):166.
    View in: PubMed
    Score: 0.368
  9. The movement disorder society and movement disorders: a modern history. Mov Disord. 2011 May; 26(6):939-46.
    View in: PubMed
    Score: 0.356
  10. [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. Rev Neurol (Paris). 2010 Jan; 166(1):1-4.
    View in: PubMed
    Score: 0.321
  11. Movement disorders caused by medical disease. Semin Neurol. 2009 Apr; 29(2):97-110.
    View in: PubMed
    Score: 0.309
  12. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
    View in: PubMed
    Score: 0.245
  13. A Unified Framework for Evidence-Based Diagnostic Criteria Programs in Movement Disorders. Mov Disord. 2023 07; 38(7):1156-1162.
    View in: PubMed
    Score: 0.205
  14. Therapies for movement disorders. Arch Neurol. 2002 May; 59(5):699-702.
    View in: PubMed
    Score: 0.191
  15. Seminal figures in the history of movement disorders: Gilles de la Tourette, Oppenheim, the Vogts, von Economo, Wilson, and Marsden. Part 12 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Sep; 16(5):940-6.
    View in: PubMed
    Score: 0.182
  16. Medical art and photography in the history of movement disorders: Part 13 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Sep; 16(5):947-53.
    View in: PubMed
    Score: 0.182
  17. History of movement disorders as a neurological specialty: Part 14 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Sep; 16(5):954-9.
    View in: PubMed
    Score: 0.182
  18. History of chorea: part 3 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Mar; 16(2):331-8.
    View in: PubMed
    Score: 0.176
  19. History of dystonia: part 4 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June, 2000. Mov Disord. 2001 Mar; 16(2):339-45.
    View in: PubMed
    Score: 0.176
  20. History of tic disorders and Gilles de la Tourette syndrome: part 5 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Mar; 16(2):346-9.
    View in: PubMed
    Score: 0.176
  21. Telemedicine Use for Movement Disorders: A Global Survey. Telemed J E Health. 2018 12; 24(12):979-992.
    View in: PubMed
    Score: 0.143
  22. Drug-induced movement disorders. Neurol Clin. 1998 Feb; 16(1):125-39.
    View in: PubMed
    Score: 0.142
  23. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018 04; 33(4):651-652.
    View in: PubMed
    Score: 0.141
  24. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994 Jul; 9(4):390-4.
    View in: PubMed
    Score: 0.111
  25. Trauma and movement disorders. Neurol Clin. 1992 Nov; 10(4):907-19.
    View in: PubMed
    Score: 0.099
  26. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.096
  27. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.083
  28. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50.
    View in: PubMed
    Score: 0.075
  29. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.075
  30. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology. 2008 Apr 15; 70(16 Pt 2):1397-402.
    View in: PubMed
    Score: 0.070
  31. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.066
  32. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.061
  33. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.060
  34. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.057
  35. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004 Sep; 19(9):1020-8.
    View in: PubMed
    Score: 0.056
  36. Movement disorders in Kuru. Mov Disord. 1999 Sep; 14(5):800-4.
    View in: PubMed
    Score: 0.040
  37. Progressive cognitive decline with truncal/limb ataxia and ballistic movements. Mov Disord. 1997 Nov; 12(6):1075-84.
    View in: PubMed
    Score: 0.035
  38. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
    View in: PubMed
    Score: 0.033
  39. Neurologic health outcomes and Agent Orange: Institute of Medicine report. Neurology. 1994 May; 44(5):801-9.
    View in: PubMed
    Score: 0.027
  40. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov; 43(11):2227-9.
    View in: PubMed
    Score: 0.026
  41. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord. 1990; 5(3):243-7.
    View in: PubMed
    Score: 0.020
  42. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology. 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3.
    View in: PubMed
    Score: 0.020
  43. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987 Dec; 10(6):522-6.
    View in: PubMed
    Score: 0.018
  44. Gilles de la Tourette on Tourette syndrome. Adv Neurol. 1982; 35:1-16.
    View in: PubMed
    Score: 0.012
  45. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med. 1978 Mar; 88(3):327-31.
    View in: PubMed
    Score: 0.009
  46. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology. 1992 Jul; 42(7):1311-4.
    View in: PubMed
    Score: 0.006
  47. Levodopa-induced myoclonus. Arch Neurol. 1975 May; 32(5):330-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.